NSCLC Liquid Biopsies and Exhaled VOC

Last updated: November 26, 2024
Sponsor: St. Joseph's Healthcare Hamilton
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lung Cancer

Non-small Cell Lung Cancer

Cancer

Treatment

N/A

Clinical Study ID

NCT06707519
14065
  • Ages > 18
  • All Genders

Study Summary

The objective of the study is to determine the feasibility of recruiting participants and using sputum, Bronchoalveolar lavage (BAL) and exhaled Volatile Organic Compounds (VOC) in addition to blood, as biological samples for detecting mutations in extracted cell-free DNA in non-small cell lung cancer (NSCLC) patients, before and after surgery, and any recurrence within a 24-month postoperative follow-up period.

This is a pilot feasibility study, proposed as a 24-month prospective, single-center, non-interventional, observational trial with NSCLC-adenocarcinoma patients indicated for resection surgery with curative intent.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient must be at least 18 years of age

  • Patient must be able to provide consent

  • Patients undergoing surgical resection with curative intent for non-small cell lungcancer at St. Joseph's Healthcare Hamilton and Firestone Institute for RespiratoryHealth.

Exclusion

Exclusion Criteria:

  • Resection done with non-curative intent or metastatic disease

  • other malignancies

  • Patients with previously treated malignancy less than 5 years prior to currentresection (not including skin cancer).

Study Design

Total Participants: 210
Study Start date:
February 01, 2023
Estimated Completion Date:
December 29, 2025

Study Description

Circulating tumor DNA (ctDNA) is increased in patients with lung cancer, and may allow detecting minimal residual disease and disease recurrence, preceding radiological detection. Detecting ctDNA in bronchoalveolar lavage/Sputum was never validated and may offer advantages over blood ctDNA, and serve as a novel biomarker for lung cancer surveillance. Lung cancer detection is possible with eNose systems with a high negative predictive value and allows prediction of treatment response to PD1 inhibitors, monitoring response to PD1 inhibitors and predicting the presence of EGFR mutations. it is reasonable to anticipate exhaled VOC to aid in detection of cancer recurrence.

The study propulsion is patients undergoing surgical resection with curative intent for NSCLC, adenocarcinoma subtype at St. Joseph's Healthcare Hamilton and the Firestone Institute of Respiratory Health , above 18 years, able to provide consent. The study procedure is collecting blood, sputum, BAL samples, exhaled VOC will be collected at the following time-points/visits: (i) Visit 1 (V1): pre surgical resection; (ii) V2: immediately before discharge from hospital post-resection; (iii) V3,4,5 : 6, 12, 24 months post-surgery; (iv) V6: unscheduled at any sign of recurrence. to note, blood sputum and BAL will be collected at visit 1 and 2 from everyone and at visits 3-6 only from those who harbor a mutation of interest.

Connect with a study center

  • St. Joseph's Healthcare Hamilton

    Hamilton, Ontario L8N 4A6
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.